Overview

Prevention of Chemotherapy Induced Cardiotoxicity in Children With Bone Tumors and Acute Myeloid Leukemia

Status:
Recruiting
Trial end date:
2021-11-01
Target enrollment:
0
Participant gender:
All
Summary
Prevention and early detection of chemotherapy-induced cardiotoxicity in children with bone tumors and Acute Myeloid Leukemia by giving capoten
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Children's Cancer Hospital Egypt 57357
Treatments:
Captopril
Criteria
Inclusion Criteria:

- All Acute Myeloid Leukemia and Bone Tumors patients (Osteosarcoma and Ewing's Sarcoma)
who didn't receive chemotherapy will be included in the study.

- Written Informed Consent from parents/guardian

Exclusion Criteria:

- Patients who received chemotherapy before starting of the study

- Patients with history of cardiac impairment, (existing or congenital heart disease).

- Patients who show intolerance or contra-indications to ACE-I.

- Patients developing acute (< 2 weeks) cardiotoxicity after the first high-dose
chemotherapy (HDC) course.